ORYZF
Price
$3.28
Change
-$0.00 (-0.00%)
Updated
Jul 24 closing price
Capitalization
237.6M
REPL
Price
$5.89
Change
-$0.01 (-0.17%)
Updated
Sep 3 closing price
Capitalization
460.14M
75 days until earnings call
Interact to see
Advertisement

ORYZF vs REPL

Header iconORYZF vs REPL Comparison
Open Charts ORYZF vs REPLBanner chart's image
Oryzon Genomics SA
Price$3.28
Change-$0.00 (-0.00%)
Volume$1K
Capitalization237.6M
Replimune Group
Price$5.89
Change-$0.01 (-0.17%)
Volume$2.55M
Capitalization460.14M
ORYZF vs REPL Comparison Chart in %
Loading...
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORYZF vs. REPL commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORYZF is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ORYZF: $3.28 vs. REPL: $5.90)
Brand notoriety: ORYZF and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORYZF: 115% vs. REPL: 33%
Market capitalization -- ORYZF: $237.6M vs. REPL: $460.14M
ORYZF [@Biotechnology] is valued at $237.6M. REPL’s [@Biotechnology] market capitalization is $460.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORYZF’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • ORYZF’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, ORYZF is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORYZF’s TA Score shows that 1 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s).

  • ORYZF’s TA Score: 1 bullish, 0 bearish.
  • REPL’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, REPL is a better buy in the short-term than ORYZF.

Price Growth

ORYZF (@Biotechnology) experienced а 0.00% price change this week, while REPL (@Biotechnology) price change was +3.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($460M) has a higher market cap than ORYZF($238M). ORYZF YTD gains are higher at: 102.469 vs. REPL (-51.280). ORYZF has higher annual earnings (EBITDA): -4.35M vs. REPL (-268.18M). REPL has more cash in the bank: 403M vs. ORYZF (31.1M). ORYZF has less debt than REPL: ORYZF (13.7M) vs REPL (76.3M). ORYZF (0) and REPL (0) have equivalent revenues.
ORYZFREPLORYZF / REPL
Capitalization238M460M52%
EBITDA-4.35M-268.18M2%
Gain YTD102.469-51.280-200%
P/E RatioN/AN/A-
Revenue00-
Total Cash31.1M403M8%
Total Debt13.7M76.3M18%
FUNDAMENTALS RATINGS
REPL: Fundamental Ratings
REPL
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ORYZFREPL
RSI
ODDS (%)
N/A
Bullish Trend 6 days ago
77%
Stochastic
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
20%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
17%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GHAAX44.11-0.04
-0.09%
VanEck Global Resources Fund A
JHQDX19.21-0.04
-0.21%
JPMorgan Hedged Equity 2 I
THOIX45.62-0.31
-0.67%
Thornburg Global Opportunities I
DHIIX19.98-0.16
-0.79%
Diamond Hill International I
PETGX14.51-0.29
-1.96%
Gabelli Pet Parents'™ A

ORYZF and

Correlation & Price change

A.I.dvisor tells us that ORYZF and REPL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORYZF and REPL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
N/A
REPL - ORYZF
30%
Poorly correlated
+9.26%
TVGN - ORYZF
24%
Poorly correlated
-2.20%
GNNSF - ORYZF
24%
Poorly correlated
N/A
IBIO - ORYZF
23%
Poorly correlated
-0.81%
BMRN - ORYZF
23%
Poorly correlated
+1.41%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+9.26%
IMNN - REPL
56%
Loosely correlated
-1.35%
SNDX - REPL
49%
Loosely correlated
-1.29%
KYMR - REPL
46%
Loosely correlated
-1.24%
ERAS - REPL
44%
Loosely correlated
+1.91%
BEAM - REPL
43%
Loosely correlated
-0.31%
More